Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant
Prevention of DMSO-Related Nausea and Vomiting by Prophylactic Administration of Ondansetron for Patients Receiving Autologous Cryopreserved Peripheral Blood Stem Cells
Sponsor: Fred Hutchinson Cancer Center
A PHASE2 clinical study on Accelerated Phase Chronic Myelogenous Leukemia and Adult Acute Lymphoblastic Leukemia in Remission, this trial is completed. The trial is conducted by Fred Hutchinson Cancer Center and has accumulated 10 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
May 2022 — Dec 2022 [monthly]
Completed PHASE2
▶ Show 5 earlier versions
-
Jan 2021 — May 2022 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jul 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Feb 2017 — Jul 2017 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Aug 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Fred Hutchinson Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .